In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives.
The in vitro and in vivo antibacterial activities of the new rifamycin derivatives KRM-1648 and KRM-1657 were compared with those of rifampin. Rifabutin, ciprofloxacin, and clarithromycin were also tested for reference. The respective MICs of KRM-1648 and KRM-1657 for 90% of the strains tested (MIC9...
Guardat en:
| Publicat a: | Antimicrob Agents Chemother |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society for Microbiology (ASM)
1994
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC188160/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8067748/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.38.5.1118 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|